n INTRODUCTION T he introduction of TNF-blocking agents since 2000 has tremendously changed the treatment of juvenile idiopathic arthritis (JIA). From randomized controlled trials there is evidence that TNF-blocking agents are efficacious and safe, but data on their long-term expected and unexpected effects remain relatively scarce. Longer follow-up of TNF-blocking agents is necessary in order to report the occurrence of adverse events (AE). To this aim, an observational study is an appropriate design (1) .
There have been few reports of biological 
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Drug survival and reasons for discontinuation of the first course of biological therapy treatment (BT) discontinuation rates and factors associated with discontinuation (2) (3) (4) . The aim of this study is to collect longterm outcome data on children receiving biological agents for JIA in terms of drug survival and to explore the reasons for biological therapy discontinuation.
n MATERIALS AND METHODS
Since November 1999 to July 2010, all JIA patients (pts) who started for the first time a BT at Pediatric Unit of Rheumatology Department of Gaetano Pini Institute, University of Milan, have been included in this prospective cohort study.
At baseline and at each visit, the following assessments were performed: the number and site of active joints, the number and site of limited joints, erythrocyte sedimentation rate and/or C-reactive protein, patient visual analogue scales (VAS 0-100 mm) for general health and for pain, physician VAS for disease activity and the CHAQ Disability Index. Treatment response to methotrexate (MTX) and previous disease-modifying antirheumatic drugs (DMARDs), and the eligibility for BT, was judged according to the ACR-Pedi30 response criteria (5) . After starting the treatment, follow-up data were collected every 2 months. AE data were collected as part of monitoring. Discontinuation was defined as cessation of the drug because of disease control according to Wallace criteria [inactive disease (ID) (6) or clinical remission on medication (CRM)], or failure. Failure was defined by AEs or inefficacy according to ACR-Pedi30, inefficacy was defined as: lack of efficacy (LaE), after a minimum period on therapy of at least 6 weeks, or loss of efficacy (LoE) after a variable period of successful treatment.
n STATISTICAL ANALYSIS
Time to discontinuation was defined according to the date of stop/switched or to the last follow-up on therapy. Statistical analysis was performed by methods suitable for the presence of competing events in survival analysis. In the competing risks setup, in fact, patients during the follow-up are exposed to the risk of stopping/switching BT for different causes, also before achieving CRM. Crude cumulative incidences (CCI) were estimated using a proper non-parametric estimator in the competing events framework and were compared by the Gray test (7) . An extension of Cox proportional hazards models which the risk of competing events is taken into account was used to estimate the specific hazard for CCI with 95% CI (8) .
Beside kind of BT, and concomitant treatment with DMARDs the following predictors were considered in the statistical analysis: gender, ILAR category, age at symptom onset, age at and disease duration before starting BT.
In the multivariable analysis, all variables above mentioned were firstly included. In the final model, gender and kind of BT were always retained, together with other predictors only if they were statistically significant (P<0.05) or if they showed moderate evidence of association (P≤0.1) with the outcome of interest.
n RESULTS
On the whole 301 JIA pts treated with one or more courses of biological drugs were enrolled. Main demographic and baseline characteristics are summarized in Table I . The majority of them (57.8%) were initially treated with etanercept (174). In total 294 pts were treated with anti-TNF agents as the first course of BT, 5 with abatacept and 2 with anakinra. In total 580 different courses of biological agents were administered to 301 pts. The median number of treatments for patient was 1 (range 1-8), ranging from 1 in persistent oligoarticular JIA to 2 and 1.5 in systemic onset JIA (so-JIA) and psoriatic arthritis respectively. More than half of treatments (323, 55.7%), were administered in monotherapy, the remaining were given in combination with one or more DMARDs. MTX (268) was Causes of discontinuation of the 1 st biological treatment and follow-up after discontinuation All 301 scrutinized patients, but 3 with no available follow-up data after their first dose of BT, were included in the analysis for drug discontinuation. The median follow-up time on treatment, as estimated by Shemper et al. (9) was about 53.7 months (range 0.45-124.45). Figure 1 shows the Kaplan-Meier analysis. In total 165/298 pts discontinued the therapy (Table II) -27 (CCI 14.51%) discontinued for ID, after reaching CRM, but among these, 13 restarted on a BT, for relapse of disease activity, after a median period free from biological drug of 6.6 months (range 2.4-28.6); -3 pts (CCI 2.3%) temporarily stopped for pregnancy. The majority of pts who suspended the 1 st biological approach for any reason (120/165), switched to a 2 nd one (117 anti-TNF and 3 non-anti-TNF). In details: 1) 64 out of the 78 pts who discontinued for AEs (12 of them after reaching CRM); 2) 53 out of the 57 pts who discontinued for failure, either for LoE 41 pts (6 after CRM) or for LaE 12 pts; 3) 3 pts out of 27 after stopping for ID, relapsed and switched to a 2 nd different biological drug. Seventeen pts discontinued for different reasons but then restarted with the same biological treatment (3 pts stopped during pregnancy and restarted after delivery, 10 pts discontinued for ID but then relapsed and restarted). Twenty-eight pts definitively stopped BT, 14 after failure (12 AEs, 2 LoE) and 14 after reaching the state of CRM. The probability of discontinuation for ID and for the other causes is shown in Figure 2 .
Discontinuation due to adverse events
Considering all first biological treatments, out of our 298 evaluated pts (during a global exposure to study drug of 800.13 pt/yrs), 78 discontinued due to an AE after a median period of therapy of 14.7 months (range 0.5-70.0). The rate of AEs was 0.097 AEs/ pt/yrs that means one withdrawal for AE every 10.27 pt/years. Among the 78 pts who failed the treatment for AEs, 62 were females: the rate of AEs (Table III) .
Discontinuation due to lack/loss of efficacy
According to the study drug, we considered 2 groups of pts: group I pts treated with the sTNFR, group II pts treated with mAbanti-TNF (infliximab and adalimumab). Pts who failed for inefficacy (LaE or LoE) were respectively: 23 out of 174 and 32 out of 120. The rate of failure was respectively: 0.05 vs 0.11 failure/pt/yrs (that means one No pts treated with non-anti-TNF drugs during their first course discontinued due to disease control, and then were excluded when fitting multivariable model. In the multivariate analysis the only predictor entered the final model for discontinuation due to inactive disease are, beside gender and BT, was disease duration. In particular, males (HR 3.5, P=0.002) and pts with shorter disease duration before starting BT shows higher remission rate (HR for 5 yrs 1.54, P=0.05).
Results from both the univariate and the multivariable models were summarized in Table IV .
n DISCUSSION Since the beginning of 2000, on the basis of controlled trials that proved the efficacy and safety of TNFa blockade in JIA, this therapeutical approach has been extensively applied in clinical practice. Biologics have revolutionized the treatment of JIA due to their efficacy, speed of onset and tolerability. Overall tolerability of anti-TNFa therapy in JIA was good in ours (1, 10) as in many other studies, but data on their longterm efficacy and safety remain relatively scarce. There have been few reports of BT discontinuation rates and factors associated with discontinuation (2-4). The aim of this study is to collect long-term outcome data on children receiving biological agents for JIA in terms of drug survival and to explore the reasons for biological therapy discontinuation. Our cohort of 301 pts treated with BT represents the more severe spectrum of JIA, those who failed to tolerate or respond to MTX and previous DMARDs and suffering from long lasting disease. Drug survival data from this 10-year-follow up study, in a real-life setting of unselected population, proves that more than 50% of pts continue the treatment at 36 months, suggesting that the majority of them find biological drug tolerable and effective. Different drug survival data have been reported by etanercept European registries (2-4, 11). Nevertheless, due to the difference in patients' numbers, duration of follow-up, and drug administered, a comparison with the European registries is difficult. The majority of pts who suspended the 1 st biological approach for any reason (120/165) switched to a second biological treatment, more frequently a further TNF-a blocking agent. The most common reasons for stopping BT in our cohort were AEs. It is interesting that infusion reactions have been the most frequently reported AEs but infliximab therapy was not a predictor of discontinuation for AEs. Data from Finnish registry (4) showed that infliximab was more often discontinued because of AEs, even if, overall treatment survival of etanercept and infliximab in JIA was comparable. In our study a significant lower chance to stop due to AEs was observed in patients with shorter disease duration before starting BT, moderate evidence was also found for male gender. In all the European cohorts (2-4, 12) systemic JIA has been previously reported to be associated with etanercept inefficacy. Also in our study the probability of discontinuation for inefficacy (lack or loss of efficacy) was associated with systemic JIA. Furthermore, in our study, the probability of discontinuation for inefficacy was associated with the use of mAb anti-TNF vs sTNFR. Our results, based on a large number of pts, showed that only few patients (#27) suspended for disease control. Nevertheless, 136 of our pts reached the CRM but in the majority of them, according to our clinical approach/judgment, to avoid a possible relapse, we preferred to maintain a long lasting treatment. Indeed half of patients (13/27), who stopped for ID, restarted therapy because of relapse of disease after a median period free from biological drug of 6.6 months. Male gender and earlier initiation of BT increased the chance to reach ID/CRM and to stop the treatment for this reason. This has been already observed in other European cohorts (11), therefore we suggest that an effective BT should be offered within a narrow time period from the disease onset. No statistically difference was found between ILAR subtypes. In conclusion, while the study confirms that BT is globally well tolerate and effective in JIA, the probability to withdrawal for disease control is low and associated with shorter disease duration at the beginning of treatment. However, the prolonged use of BT provides objective surrogate information of clinical benefit during first biological course.
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